Selection of chemotherapy for hyperthermic intraperitoneal use in gastric cancer
Braam, H.J, Schellens, J.H, Boot, H, van Sandick, J.W, Knibbe, C.A, Boerma, D, van Ramshorst, B
Published in Critical reviews in oncology/hematology (01.09.2015)
Published in Critical reviews in oncology/hematology (01.09.2015)
Get full text
Journal Article
505 Clinical evidence of intra-tumoral immune activation and tumor targeting with RG, a CEA-targeted engineered IL-2 immunocytokine
Tabernero, J, Homicsko, K, Schellens, J.H, Hoekstra, O, Van der Veen, L, Melero, I, és, G. Argil, Mau-Sorensen, M, Angevin, E, Joensuu, H, Van Brummelen, E, van Oordt, C.W. Menke-van der Houven, Nayak, T, Romagnoli, S, Reis, B, Brossard, S. Soehrman, Evers, S, Saro, J, Verheul, H, Lassen, U
Published in European journal of cancer (1990) (01.09.2015)
Published in European journal of cancer (1990) (01.09.2015)
Get full text
Journal Article
Time Dependent Resource Use and Costs Associated with Different States of Disease in Patients Diagnosed with HER-2 Positive Metastatic Breast Cancer
Frederix, G.W, Severens, J.L, Hövels, A.M, van Hasselt, J.G, Raaijmakers, J.A, Schellens, J.H
Published in Value in health (01.11.2013)
Published in Value in health (01.11.2013)
Get full text
Journal Article
PRM46 Development of a Framework for Cost-Effectiveness Analysis Cohort Simulation Using an Ordinary Differential Equation Solver Algorithm in R
Frederix, G.W, van Hasselt, J.G, Severens, J.L, Hövels, A.M, Huitema, A.D, Raaijmakers, J.A, Schellens, J.H
Published in Value in health (01.11.2012)
Published in Value in health (01.11.2012)
Get full text
Journal Article
MO2 Impact of Structural Assumptions on Cost-Effectiveness Outcomes: Towards a Standardized Cost-Effectiveness Model for Adjuvant Breast Cancer Therapies
Frederix, G.W, Van hasselt, J.G, Schellens, J.H, Hövels, A.M, Huitema, A.D, Raaijmakers, J.A, Severens, J
Published in Value in health (01.11.2012)
Published in Value in health (01.11.2012)
Get full text
Journal Article
651 DISCUSSION Pharmacodynamic evaluation of pCDC2 and Wee1 signature as biomarkers of target engagement for the Wee1 tyrosine kinase inhibitor MK-1775
Cheng, J.D, Tibes, R, Schellens, J.H, Shapiro, G.I, Pavlick, A.C, Oza, A.M, Xu, Y, Song, Y, Lam, R.L.H, Demuth, T
Published in European journal of cancer supplements (2010)
Published in European journal of cancer supplements (2010)
Get full text
Journal Article
PCN191 - COST-EFFECTIVENESS OF MONITORING ENDOXIFEN LEVELS IN BREAST CANCER PATIENTS ADJUVANTLY TREATED WITH TAMOXIFEN
Vreman, R., van Nuland, M., ten Ham, R.M., de Vries-Schultink, A.H., Rosing, H., Schellens, J.H., Beijnen, J.H., Hovels, A.M.
Published in Value in health (01.10.2018)
Published in Value in health (01.10.2018)
Get full text
Journal Article
Clinical evaluation of AZD1152, an i.v. inhibitor of Aurora B kinase, in patients with solid malignant tumors
Boss, D.S., Witteveen, P.O., van der Sar, J., Lolkema, M.P., Voest, E.E., Stockman, P.K., Ataman, O., Wilson, D., Das, S., Schellens, J.H.
Published in Annals of oncology (01.02.2011)
Published in Annals of oncology (01.02.2011)
Get full text
Journal Article
Individualized Pharmacokinetically-Guided Dosing of Pazopanib: a Feasibility Study in Cancer Patients
Verheijen, R., Bins, S., Gadellaa-van Hooijdonk, C.G., Mathijssen, R.H.J., Lolkema, M.P., van Doorn, L., Rotteveel-Buchholtz, K., Schellens, J.H., Beijnen, J.H., Huitema, A.D.R., Steeghs, N.
Published in Annals of oncology (01.09.2014)
Published in Annals of oncology (01.09.2014)
Get full text
Journal Article
486PINDIVIDUALIZED PHARMACOKINETICALLY-GUIDED DOSING OF PAZOPANIB: A FEASIBILITY STUDY IN CANCER PATIENTS
Verheijen, R., Bins, S., Gadellaa-van Hooijdonk, C.G., Mathijssen, R.H.J., Lolkema, M.P., van Doorn, L., Rotteveel-Buchholtz, K., Schellens, J.H., Beijnen, J.H., Huitema, A.D.R., Steeghs, N.
Published in Annals of oncology (01.09.2014)
Published in Annals of oncology (01.09.2014)
Get full text
Journal Article
PRM19 - Time Dependent Resource Use and Costs Associated with Different States of Disease in Patients Diagnosed with HER-2 Positive Metastatic Breast Cancer
Frederix, G.W., Severens, J.L., Hövels, A.M., van Hasselt, J.G., Raaijmakers, J.A., Schellens, J.H.
Published in Value in health (01.11.2013)
Published in Value in health (01.11.2013)
Get full text
Journal Article
Outcome of patients with sarcoma and other mesenchymal tumours participating in phase I trials: a subset analysis of a European Phase I database
Cassier, P.A., Polivka, V., Judson, I., Soria, J.-C., Penel, N., Marsoni, S., Verweij, J., Schellens, J.H., Morales-Barrera, R., Schöffski, P., Voest, E.E., Gomez-Roca, C., Evans, T.R.J., Plummer, R., Gallerani, E., Kaye, S.B., Olmos, D.
Published in Annals of oncology (01.06.2014)
Published in Annals of oncology (01.06.2014)
Get full text
Journal Article
Predicting clinical benefit from everolimus in patients with advanced solid tumors, the CPCT-03 study
Weeber, Fleur, Cirkel, Geert A, Hoogstraat, Marlous, Bins, Sander, Gadellaa-van Hooijdonk, Christa G M, Ooft, Salo, van Werkhoven, Erik, Willems, Stefan M, van Stralen, Marijn, Veldhuis, Wouter B, Besselink, Nicolle J M, Horlings, Hugo M, Steeghs, Neeltje, de Jonge, Maja J, Langenberg, Marlies H G, Wessels, Lodewyk F A, Cuppen, Edwin P J G, Schellens, J H, Sleijfer, Stefan, Lolkema, Martijn P, Voest, Emile E
Published in Oncotarget (15.08.2017)
Published in Oncotarget (15.08.2017)
Get full text
Journal Article
Two-protein signature of novel serological markers apolipoprotein-A2 and serum amyloid alpha predicts prognosis in patients with metastatic renal cell cancer and improves the currently used prognostic survival models
Vermaat, J.S., van der Tweel, I., Mehra, N., Sleijfer, S., Haanen, J.B., Roodhart, J.M., Engwegen, J.Y., Korse, C.M., Langenberg, M.H., Kruit, W., Groenewegen, G., Giles, R.H., Schellens, J.H., Beijnen, J.H., Voest, E.E.
Published in Annals of oncology (01.07.2010)
Published in Annals of oncology (01.07.2010)
Get full text
Journal Article
644 POSTER The novel oral taxane BMS275183 has a favorable activity and toxicity profile in a twice weekly schedule; Preliminary findings from an extended phase I trial
Bröker, L.E., Veltkamp, S., Heath, E., Gall, H., Kuenen, B.C., Voi, M., Kayitalire, L., Lorusso, P.M., Schellens, J.H., Giaccone, G.
Published in European journal of cancer supplements (01.11.2006)
Published in European journal of cancer supplements (01.11.2006)
Get full text
Journal Article
Activity and toxicity of GI147211 in breast, colorectal and non-small-cell lung cancer patients: An EORTC—ECSG phase II clinical study
Gamucci, T., Paridaens, R., Heinrich, B., Schellens, J. H., Pavlidis, N., Verweij, J., Sessa, C., Kaye, S., Roelvink, M., Wanders, J., Hanauske, A.
Published in Annals of oncology (01.07.2000)
Published in Annals of oncology (01.07.2000)
Get full text
Journal Article
Therapeutic drug monitoring of non-anticancer drugs in cancer patients
Joerger, M, Schellens, J H M, Beijnen, J H
Published in Methods and findings in experimental and clinical pharmacology (01.09.2004)
Published in Methods and findings in experimental and clinical pharmacology (01.09.2004)
Get more information
Journal Article